July 10 (Reuters) - Amylyx Pharmaceuticals Inc ( AMLX ):
* AMYLYX PHARMACEUTICALS ANNOUNCES ACQUISITION OF PHASE
3-READY
GLP-1 RECEPTOR ANTAGONIST (AVEXITIDE) WITH FDA BREAKTHROUGH
THERAPY DESIGNATION
* AMYLYX PHARMACEUTICALS INC ( AMLX ) - AVEXITIDE TO ENTER PHASE 3
TRIALS
IN Q1 2025
* AMYLYX PHARMACEUTICALS ( AMLX ): ENGAGING IN TALKS WITH BROADER
CONGENITAL HI COMMUNITY TO DEVELOP PATH FORWARD BASED ON
PROMISING PHASE 2 STUDY RESULTS
Source text for Eikon:
Further company coverage: